激活剂(遗传学)
周围神经病变
异柠檬酸脱氢酶
医学
药理学
糖尿病神经病变
癌症研究
糖尿病
酶
外围设备
人参皂甙
病理
化学
作者
Yujie Huang,Yuxi Wei,Sujie Xie,Qiuhui Li,Fan Zhou,Yan Ma,Yuan Ruan,Shizhao Ji,Jiaying Wang,Xu Shen
标识
DOI:10.1016/j.jare.2026.03.055
摘要
INTRODUCTION: Diabetic peripheral neuropathy (DPN) is a severe diabetic complication closely associated with diabetic foot that is a major risk factor for amputation and mortality. Hyperglycemia disrupts the tricarboxylic acid (TCA) cycle, thereby coupling metabolic disorders to DPN pathogenesis. However, the underlying mechanisms remain unclear. OBJECTIVES: This study aimed to explore the role of isocitrate dehydrogenase 1 (IDH1), a key TCA cycle enzyme, in DPN pathogenesis using clinical samples and mouse models. METHODS: Serum and sciatic nerve (SN) tissues from patients with DPN, individuals without diabetes, and type 1/2 diabetic mice with DPN were analyzed. IDH1 activators were screened from the lab in-house compound library. To investigate the mechanism underlying the regulation of IDH1 in DPN pathogenesis, a proteomics-based assay using the discovered IDH1 activator as a probe was performed and verified in the SN tissues of DPN mice, clinical samples and IDH1-knockdown DPN mice that were generated using adeno-associated virus php.s-IDH1-RNAi. RESULTS: IDH1 activity and its catalytic product, α-ketoglutarate, were pathologically repressed in patients with DPN and model mice. Ginsenoside Rb1 (Rb1) was identified as an IDH1 activator and could counteract the methylglyoxal (a diabetes-associated metabolite)-mediated IDH1 inhibition. Rb1-mediated pharmacological activation of IDH1 effectively alleviated DPN pathology by improving ribosomal dysfunction, enhancing mitochondrial biogenesis and suppressing neuroinflammation. CONCLUSION: Our findings highlight the potent role of TCA cycle dysfunction in DPN progression and reveal that pharmacological IDH1 activation is a promising therapeutic strategy against DPN, while Rb1 shows high potential for treating this disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI